Skip to content

Precigen PGEN Change in AR

Change in AR at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.2M+99.8%
Gilead Sciences logo
Gilead SciencesGILD
-$134M-69.6%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$5.56M+826%
Arrowhead Research logo
Arrowhead ResearchARWR
$212.05M+8,382%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$19M-90.0%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$0+100%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's change in AR?
Precigen (PGEN) reported change in AR of $22.49M in Q1 2026.
How has Precigen's change in AR changed year-over-year?
Precigen's change in AR increased by 12949.7% year-over-year, from -$175K to $22.49M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.